Open Label Study of BAY1082439 in Patients With Advanced Cancer

Inclusion Criteria

• •Subjects with advanced, histologically or cytologically confirmed solid tumors, refractory to any standard therapy, have no standard therapy available, or subjects must have actively refused any treatment which would be regarded standard, and / or if in the judgment of the investigator, experimental treatment is clinically and ethically acceptable
• •* Expansion phase only: Subjects with histologically or cytologically confirmed, locally advanced or metastatic endometrial cancer or breast cancer or iNHL, who are refractory to or have exhausted all available therapies
• •International normalized ratio (INR) and partial thromboplastin time (PTT) \<1.5 x ULN \[Subjects on anticoagulation with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.\] For subjects on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre-dose, as defined by the local standard of care
• •Measurable or evaluable disease
• •Life expectancy of at least 12 weeks
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• •Adequate bone marrow, liver and renal function